Abstract:The optimal delay time after intravenous (i.v.) administration of contrast medium (CM) for opacification of the upper urinary tract (UUT) for multidetector computed tomography urography (MDCTU) was investigated. UUT opacification was retrospectively evaluated in 36 four-row MDCTU examinations. Single- (n=10) or dual-phase (n=26) MDCTU was performed with at least 5-min delay after i.v. CM. UUT was divided into four sections: intrarenal collecting system (IRCS), proximal, middle and distal ureter. Two independen… Show more
“…If a corticomedullary phase is employed, data acquisition is usually started 25-35 s after start of CM injection [9,22]. The nephrographic phase starts after a delay of 90-110 s after start of the CM injection [9,23,28,30,32,33,37], while for the final excretory phase a fixed delay of 240-480 s after the start of CM injection has been used [9,[28][29][30]32]. In more recent times, excretory phase data acquisition has been further delayed to 720 s for improved depiction of the lower ureter [38].…”
Section: Intravenous Injection Of CMmentioning
confidence: 99%
“…Single-bolus CM injections use 100-150 ml of nonionic CM (300-370 mgI/ml) injected at a rate of 2-3 ml/s [9,22,23,[28][29][30][31][32][33][34][35][36][37]. If a corticomedullary phase is employed, data acquisition is usually started 25-35 s after start of CM injection [9,22].…”
The aim was to develop clinical guidelines for multidetector computed tomography urography (CTU) by a group of experts from the European Society of Urogenital Radiology (ESUR). Peer-reviewed papers and reviews were systematically scrutinized. A summary document was produced and discussed at the ESUR 2006 and ECR 2007 meetings with the goal to reach consensus. True evidence-based guidelines could not be formulated, but expert guidelines on indications and CTU examination technique were produced. CTU is justified as a first-line test for patients with macroscopic haematuria, at high-risk for urothelial cancer. Otherwise, CTU may be used as a problem-solving examination. A differential approach using a one-, two- or three-phase protocol is proposed, whereby the clinical indication and the patient population will determine which CTU protocol is employed. Either a combined nephrographic-excretory phase following a split-bolus intravenous injection of contrast medium, or separate nephrographic and excretory phases following a single-bolus injection can be used. Lower dose (CTDIvol 5-6 mGy) is used for benign conditions and normal dose (CTDIvol 9-12 mGy) for potential malignant disease. A low-dose (CTDIvol 2-3 mGy) unenhanced series can be added on indication. The expert-based CTU guidelines provide recommendations to optimize techniques and to unify the radiologist's approach to CTU.
“…If a corticomedullary phase is employed, data acquisition is usually started 25-35 s after start of CM injection [9,22]. The nephrographic phase starts after a delay of 90-110 s after start of the CM injection [9,23,28,30,32,33,37], while for the final excretory phase a fixed delay of 240-480 s after the start of CM injection has been used [9,[28][29][30]32]. In more recent times, excretory phase data acquisition has been further delayed to 720 s for improved depiction of the lower ureter [38].…”
Section: Intravenous Injection Of CMmentioning
confidence: 99%
“…Single-bolus CM injections use 100-150 ml of nonionic CM (300-370 mgI/ml) injected at a rate of 2-3 ml/s [9,22,23,[28][29][30][31][32][33][34][35][36][37]. If a corticomedullary phase is employed, data acquisition is usually started 25-35 s after start of CM injection [9,22].…”
The aim was to develop clinical guidelines for multidetector computed tomography urography (CTU) by a group of experts from the European Society of Urogenital Radiology (ESUR). Peer-reviewed papers and reviews were systematically scrutinized. A summary document was produced and discussed at the ESUR 2006 and ECR 2007 meetings with the goal to reach consensus. True evidence-based guidelines could not be formulated, but expert guidelines on indications and CTU examination technique were produced. CTU is justified as a first-line test for patients with macroscopic haematuria, at high-risk for urothelial cancer. Otherwise, CTU may be used as a problem-solving examination. A differential approach using a one-, two- or three-phase protocol is proposed, whereby the clinical indication and the patient population will determine which CTU protocol is employed. Either a combined nephrographic-excretory phase following a split-bolus intravenous injection of contrast medium, or separate nephrographic and excretory phases following a single-bolus injection can be used. Lower dose (CTDIvol 5-6 mGy) is used for benign conditions and normal dose (CTDIvol 9-12 mGy) for potential malignant disease. A low-dose (CTDIvol 2-3 mGy) unenhanced series can be added on indication. The expert-based CTU guidelines provide recommendations to optimize techniques and to unify the radiologist's approach to CTU.
“…It has previously been shown that delay time for CTU in the excretory phase after i.v.administration of contrast media is crucial for the proportion of urinary tract segments completely delineated, particularly for the distal ureter [5][6][7]. Delay time for the excretory phase exceeded 10 min in most patients, which is usually associated with increased success at delineating the ureter [3,[5][6][7]. Ancillary manoeurvres were restricted to the i.v.…”
Section: Discussionmentioning
confidence: 99%
“…hydration of the patient, i.v. administration of low doses of frusemide prior to CTU [6][7][8], and obtaining additional CT images in the excretory phase [9]. However, one major concern in CTU is additional radiation exposure due to (repetitive) CT data acquisitions in the excretory phase [3,10].…”
Section: Introductionmentioning
confidence: 99%
“…It has been demonstrated that the quality of depiction and delineation of the upper urinary tract at CTU in the excretory phase can be improved by means of optimizing delay times for imaging after i.v. administration of contrast media [5][6][7], i.v. hydration of the patient, i.v.…”
Malignant tumors of the female pelvis account for 12-13% of newly diagnosed solid neoplasms among women in the USA and Germany. German guidelines advocate diagnostic imaging for local recurrence and metastasis while there are no recommendations for primary tumors. As excretory urography has been replaced by the excretory phase of computed tomography urography (CTU) in many institutions, two independent observers retrospectively evaluated CTUs of primary or recurrent female pelvic tumors to rule out associations between CTU findings and subsequent urologic measures. Among 31 CTUs of 27 women (age 29-84 years, mean 57 years) with 15 primary and 13 recurrent tumors, 83-100% of unremarkable proximal, middle and distal ureter segments were completely delineated in the excretory phase (delay 6-29 min, mean 16 min). The most common pathological findings included distal ureter obstruction (n=19, 61%), bladder compression (n=13, 42%) and bladder invasion (n=8, 26%). Out of 20 pathologically altered urinary tracts 8 were subsequently subjected to urologic measures (2-tailed Fisher exact test, p=0.0215) but none of the 10 unremarkable urinary tracts were treated. It appears that CTU is a sensible pre-therapeutic test for the urinary tract for primary and recurrent female pelvic tumors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.